Journal
NEUROLOGY
Volume 99, Issue 7, Pages 34-41Publisher
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1212/WNL.0000000000200238
Keywords
-
Categories
Funding
- Parkinson's Foundation [PF-MET-2011]
Ask authors/readers for more resources
This article outlines the principles of drug selection for prevention trials in Parkinson disease (PD), based on the expanding knowledge of genetic determinants and prodromal features of the disease. The article describes relatively low-risk drug candidates for specific at-risk populations and reviews gene-targeted approaches for their potential in future prevention trials.
Despite the sound epidemiologic and basic science rationales underpinning numerous disease modification trials in manifest Parkinson disease (PD), none has convincingly demonstrated that a treatment slows progression. Rapidly expanding knowledge of the genetic determinants and prodromal features of PD now allows realistic planning of prevention trials with initiation of putatively neuroprotective therapies earlier in the disease. In this article, we outline the principles of drug selection for PD prevention trials, focused on proof-of-concept opportunities that will help establish a methodological foundation for this fledgling field. We describe prototypical, relatively low-risk drug candidates for such trials (e.g., albuterol, ambroxol, caffeine, ibuprofen), tailored to specific at-risk populations ranging from pathogenic LRRK2 or GBA gene variant carriers to those defined by prodromal PD and alpha-synucleinopathy. Finally, we review gene-targeted approaches currently in development targeting clinically manifest PD for their potential in future prevention trials.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available